Cursos

← vista completa

Publicado el 1 de enero de 2004 | http://doi.org/10.5867/medwave.2004.01.3558

Impacto de las estatinas en la enfermedad cardiovascular

Impact of statins on cardiovascular disease

Mónica Acevedo

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Mónica Acevedo

Cardióloga, Hospital Clínico Pontificia Universidad Católica de Chile, Santiago, Chile

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Acevedo M. Impact of statins on cardiovascular disease. Medwave 2004;4(01):e3558 doi: 10.5867/medwave.2004.01.3558

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/01/2004

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995 May 20;345(8960):1274-5. | PubMed
  2. Pfeffer MA, Sacks FM, Moyé LA, East C, Goldman S, Nash DT, et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol and Recurrent Events. J Am Coll Cardiol 1999 Jan;33(1):125-30. | CrossRef | PubMed
  3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301-7. | CrossRef | PubMed
  4. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001 May 1;87(9):1074-9. | CrossRef | PubMed
  5. Hoogwerf BJ, Waness A, Cressman M, Canner J, Campeau L, Domanski M, et al. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes. 1999 Jun;48(6):1289-94. | CrossRef | PubMed
  6. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2005-16. | CrossRef | PubMed
  7. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, Engl J Med. 1999 Aug 5; 341(6):410-8. | PubMed